论文部分内容阅读
目的探讨肺表面活性物质对足月新生儿急性呼吸窘迫综合征治疗的疗效及预后分析。方法 110例足月的新生儿随机分为观察组和对照组,每组55例。对照组予以常规临床方法进行治疗,观察组在此基础上予以肺表面活性物质的方法进行治疗。观察并比较两组患儿治疗后的临床疗效以及恢复时间。结果观察组患儿治疗总有效率(80%)明显高于对照组(60%),差异具有统计学意义(P<0.05);观察组患者在接受治疗恢复时间(46.12±2.34)h明显短于对照组患者的(58.23±3.56)h,差异具有统计学意义(P<0.05)。结论应用肺表面活性物质治疗新生儿急性呼吸窘迫综合征的临床疗效显著,能够有效改善患者的临床症状,缩短恢复时间,值得在临床上广泛推广应用。
Objective To investigate the efficacy and prognosis of pulmonary surfactant in the treatment of full-term neonatal acute respiratory distress syndrome. Methods One hundred and ten newborn infants were randomly divided into observation group and control group with 55 cases in each group. The control group was treated with routine clinical methods, and the observation group was treated with pulmonary surfactant on the basis of this. The clinical efficacy and recovery time after treatment in both groups were observed and compared. Results The total effective rate (80%) in observation group was significantly higher than that in control group (60%), the difference was statistically significant (P <0.05). The recovery time of observation group was significantly shorter at 46.12 ± 2.34 h In the control group (58.23 ± 3.56) h, the difference was statistically significant (P <0.05). Conclusion The application of pulmonary surfactant in the treatment of neonatal acute respiratory distress syndrome has significant clinical curative effect, which can effectively improve the clinical symptoms and shorten the recovery time of patients, and is worth popularizing in clinic.